SCHEMBL10025802

SCHEMBL10025802

c1ccc2c(c1)ccc1sc3ccccc3c1ccc1ccccc1c1c3ccccc3c2c2ccccc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 1/20 0.58
ALDH1A1 P00352 4/20 0.47
HPGD P15428 3/20 0.47
RAB9A P51151 2/20 0.47
MAPT P10636 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HPRT1 P00492 1/20 0.46
NQO1 P15559 1/20 0.45
NQO2 P16083 1/20 0.45
HSD17B10 Q99714 4/20 0.44
TDP1 Q9NUW8 3/20 0.44
TSHR P16473 2/20 0.44
CYP2A6 P11509 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
HIF1A Q16665 2/20 0.44
CYP3A4 P08684 1/20 0.44
MAPK1 P28482 1/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44
ATM Q13315 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29436076 0.85 GPR3 (0.54) GPR3ALDH1A1HPGDRAB9AMAPT
SCHEMBL29702995 0.85 GPR3 (0.54) GPR3ALDH1A1HPGDRAB9AMAPT
SCHEMBL9537997 0.85 GPR3 (0.54) GPR3ALDH1A1HPGDRAB9AMAPT
SCHEMBL2606564 0.82 GPR3 (0.46) GPR3ALDH1A1HPGDRAB9AMAPT
SCHEMBL30062535 0.82 HSD17B10 (0.52) GPR3ALDH1A1HPGDRAB9AHPRT1
SCHEMBL13250616 0.82 HSD17B10 (0.52) GPR3ALDH1A1HPGDRAB9AHPRT1
Phenanthrene SCHEMBL16752562 0.82 GPR3 (0.70) GPR3ALDH1A1HPGDRAB9AMAPT
SCHEMBL4847084 0.82 HPRT1 (0.67) ALDH1A1HPGDRAB9AHPRT1HSD17B10
SCHEMBL29517920 0.82 HPRT1 (0.67) ALDH1A1HPGDRAB9AHPRT1HSD17B10
SCHEMBL18767506 0.82 GPR3 (0.50) GPR3ALDH1A1HPGDRAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124249-B2 Derivatives of fused aromatic systems; stability; sublimation stability; easy to purify due to better solubilty; easy reproducibility because do not form isomers MERCK PATENT GMBH (DE) 2012-02-28 US disclosed
US-8124249-B2 Derivatives of fused aromatic systems; stability; sublimation stability; easy to purify due to better solubilty; easy reproducibility because do not form isomers MERCK PATENT GMBH (DE) 2012-02-28 US disclosed
US-20080171225-A1 Novel Materials For Organic Electroluminescent Devices MERCK PATENT GMBH (DE) 2008-07-17 US disclosed
US-20080171225-A1 Novel Materials For Organic Electroluminescent Devices MERCK PATENT GMBH (DE) 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171225-A1 Novel Materials For Organic Electroluminescent Devices OR10J3, EML4, TYR GPR3 3641/4885ALDH1A1 1325/4885HPGD 3418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.